iBio, Inc.

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and

Stockholders of iBio, Inc. and Subsidiaries

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of iBio, Inc. and Subsidiaries (the “Company”) as of June 30, 2026 and 2025, and the related statements of operations and comprehensive loss, stockholders’ equity, and cash flows for each of the years in the two year period ended June 30, 2026, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2026 and 2025, and the results of its operations and its cash flows for each of the years in the two year period ended June 30, 2026, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters

The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

Impairment of Indefinite-Lived Asset IBIO-101

As disclosed in Notes 5 and 11 to the consolidated financial statements, the Company acquired the IBIO-101 indefinite-lived intangible asset in connection with the RubrYc stock purchase and asset acquisition. During the year ended June 30, 2026, the Company recorded impairment charges totaling $5.0 million, consisting of approximately $2.5 million during the three-month period ended December 31, 2025 and the remaining $2.5 million during the three-month period ended March 31, 2026, reducing the carrying value of the asset to $0 as of June 30, 2026 (June 30, 2025: $5.0 million).

The Company estimated the fair value of the asset using an income approach (Multi-Period Excess Earnings Method). That estimate depended on significant management assumptions, including projected future revenue, future development costs, the probability of technical and regulatory success across development phases, projected post-launch cash flows, and the discount rate. Changes in these assumptions could have a significant effect on the estimated fair value and the amount of the impairment charge.

We identified the impairment of IBIO-101 as a critical audit matter because auditing management's fair value estimate involved especially challenging, subjective, and complex auditor judgment, including the involvement of professionals with specialized valuation skill, given the sensitivity of the estimate to the underlying assumptions.

How the Critical Audit Matter was addressed in the Audit

Our audit procedures related to the impairment of IBIO-101 included, among others:

/s/ GRASSI & Co., CPAs, P.C.

​

We have served as the Company’s auditor since 2024.

​

Jericho, New York

​

August 27, 2026

​

iBio, Inc. and Subsidiaries